"Mediastinal hematolymphoid tumours adopt Lugano staging, redefine unclassified B-cell lymphomas as “mediastinal gray zone lymphoma,” and focus on entities with mediastinal features 2, 6."
"TNM staging now requires histopathologic confirmation and includes histologic grading and type. Full staging (I–IV) is provided for lung carcinomas (non-small cell, small cell, carcinoid), pleural mesothelioma, and thymic tumours. For other thoracic soft tissue tumours, only TNM categories are assigned, and no staging is provided for entities like Kaposi sarcoma, dermatofibrosarcoma, fibromatosis, or angiosarcoma. Regional lymph nodes are defined from the supraclavicular area to the diaphragm 1."
"Mediastinal hematolymphoid tumours adopt Lugano staging, redefine unclassified B-cell lymphomas as “mediastinal gray zone lymphoma,” and focus on entities with mediastinal features 2, 6."
"In the 5th edition, the term “variant” has been replaced with “subtype” to reserve “variant” for genetic variations. Tumours that cannot be fully categorised, often due to limited biopsy samples, are designated as “not otherwise specified” (NOS) 1."
"TNM Staging of lung, pleura, and thymic tumours"
"TNM staging now requires histopathologic confirmation and includes histologic grading and type. Full staging (I–IV) is provided for lung carcinomas (non-small cell, small cell, carcinoid), pleural mesothelioma, and thymic tumours. For other thoracic soft tissue tumours, only TNM categories are assigned, and no staging is provided for entities like Kaposi sarcoma, dermatofibrosarcoma, fibromatosis, or angiosarcoma. Regional lymph nodes are defined from the supraclavicular area to the diaphragm 1."
"TNM staging now requires histopathologic confirmation and includes histologic grading and type. Full staging (I–IV) is provided for lung carcinomas (non-small cell, small cell, carcinoid), pleural mesothelioma, and thymic tumours. For other thoracic soft tissue tumours, only TNM categories are assigned, and no staging is provided for entities like Kaposi sarcoma, dermatofibrosarcoma, fibromatosis, or angiosarcoma. Regional lymph nodes are defined from the supraclavicular area to the diaphragm 1."
"nut carcinoma of the lung (see NUT carcinoma of the thorax)"
"diffuse mesothelioma, NOS"
"NUT carcinoma of the thorax"
"adenocarcinoma NOS of the thymus"
"thymic carcinoma NOS"
"The major changes, in tumours of the lung, constituted the use of immunohistochemistry in all the tumour classifications, personalized molecular testing to help with treatment strategy of advanced lung cancer, a new classification system for small biopsies and cytology, altogether different approach to adenocarcinoma of the lung, limiting the use of large cell carcinoma and reclassifying of other large cell carcinomas, reclassifying of squamous cell carcinoma into subtypes, grouping neuroendocrine tumour in one category, adding multiple entities such as myoepithelioma, myoepithelial carcinoma and NUT carcinoma, changing of names from hamartoma to pulmonary hamartoma, sclerosing haemangioma to sclerosing pneumocytoma, recognition of genetic translocation related to pulmonary myxoid sarcoma and epithelioid haemangioendothelioma, creation of a group of PEComatous tumours, including Erdheim-Chester disease to lymphoproliferative tumours, and grouping of tumours of ectopic origin to include germ cell tumours, intrapulmonary thymoma, melanoma and meningioma."
"haematolymphoid tumours of the mediastinum: Introduction"
Expected headings
"Main changes in the 5th edition (2021)"
"Terminology"
"TNM Staging of lung, pleura, and thymic tumours"
"Essential and desirable diagnostic criteria"
"Tumours of the lung"
"Epithelial tumours"
"Lung neuroendocrine neoplasms"
"Mesenchymal tumours specific to the lung"
"PEComatous tumours"
"Haematolymphoid tumours"
"Tumours of the pleura and pericardium"
"Mesothelial tumours"
"Haematolymphoid tumours"
"Tumours of the heart"
"Benign tumours"
"Malignant tumours"
"Haematolymphoid tumours"
"Mesenchymal tumours of the thorax"
"Adipocytic tumours"
"Vascular tumours"
"Skeletal muscle tumours"
"Tumours of uncertain differentiation"
"Tumours of the thymus"
"Epithelial tumours"
"Thymic neuroendocrine neoplasms"
"Germ cell tumours of the mediastinum"
"Haematolymphoid tumours of the mediastinum"
"Ectopic tumours of thyroid and parathyroid origin"
"Metastases"
"Genetic tumour syndromes involving the thorax"
"Main changes in the 4th edition (2015)"
"The major changes, in tumours of the lung, constituted the use of immunohistochemistry in all the tumour classifications, personalized molecular testing to help with treatment strategy of advanced lung cancer, a new classification system for small biopsies and cytology, altogether different approach to adenocarcinoma of the lung, limiting the use of large cell carcinoma and reclassifying of other large cell carcinomas, reclassifying of squamous cell carcinoma into subtypes, grouping neuroendocrine tumour in one category, adding multiple entities such as myoepithelioma, myoepithelial carcinoma and NUT carcinoma, changing of names from hamartoma to pulmonary hamartoma, sclerosing haemangioma to sclerosing pneumocytoma, recognition of genetic translocation related to pulmonary myxoid sarcoma and epithelioid haemangioendothelioma, creation of a group of PEComatous tumours, including Erdheim-Chester disease to lymphoproliferative tumours, and grouping of tumours of ectopic origin to include germ cell tumours, intrapulmonary thymoma, melanoma and meningioma."
"The major changes, in tumours of the lung, constituted the use of immunohistochemistry in all the tumour classifications, personalized molecular testing to help with treatment strategy of advanced lung cancer, a new classification system for small biopsies and cytology, altogether different approach to adenocarcinoma of the lung, limiting the use of large cell carcinoma and reclassifying of other large cell carcinomas, reclassifying of squamous cell carcinoma into subtypes, grouping neuroendocrine tumour in one category, adding multiple entities such as myoepithelioma, myoepithelial carcinoma and NUT carcinoma, changing of names from hamartoma to pulmonary hamartoma, sclerosing haemangioma to sclerosing pneumocytoma, recognition of genetic translocation related to pulmonary myxoid sarcoma and epithelioid haemangioendothelioma, creation of a group of PEComatous tumours, including Erdheim-Chester disease to lymphoproliferative tumours, and grouping of tumours of ectopic origin to include germ cell tumours, intrapulmonary thymoma, melanoma and meningioma."